Document Detail


Hypertension therapy and cardiovascular protection. Effects of angiotensin II receptor block with Valsartan.
MedLine Citation:
PMID:  22195356     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: Arterial hypertension and its pharmacological control are discussed in view of the high cardiovascular risk due to lack of target blood pressure achievement. It is, therefore, underlined the need for a highly effective therapy, able to provide protection from organ damage through a marked antihypertensive activity. In addition to this basic property, also compliance of the patient to therapy is needed, in order to avoid that the effects of therapeutic measures should result fruitless.
DISCUSSION AND CONCLUSIONS: An answer to this problem appears now offered by a recent class of antihypertensive agents, the angiotensin II receptor blockers (ARBs). Among them valsartan has been described, providing an overview of methodologically adequate clinical studies, evaluating the efficacy, even at long-term, and safety. Valsartan has been compared with other antihypertensive agents of proven efficacy, mainly amlodipine, showing a better clinical profile. A wide room was finally left to the problem of adherence to therapy, whose lack is associated very frequently with marked increases in cardiovascular risk, due to absent or insufficient blood pressure control. This implies significant increases of health costs, as documented in numerous Countries, mainly following the higher need for hospitalization. On the other hand, it is also well documented the pharmacoeconomic benefit associated to ARBs use, particularly with valsartan.
Authors:
A Sestito
Related Documents :
15834766 - Does peripheral nerve degeneration affect circulatory responses to head-up tilt in spin...
12807346 - Dose-response related efficacy in orthostatic hypotension of a fixed combination of d-c...
7165556 - The effect of acetate and bicarbonate dialysis on orthostatic blood pressure regulation.
8553876 - Central blood volume influences sympathetic sudomotor nerve traffic in warm humans.
2285616 - Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension.
7744466 - Repair of experimental atrial rupture with fibrin glue.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  European review for medical and pharmacological sciences     Volume:  15     ISSN:  1128-3602     ISO Abbreviation:  Eur Rev Med Pharmacol Sci     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-12-26     Completed Date:  2012-01-17     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  9717360     Medline TA:  Eur Rev Med Pharmacol Sci     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  1247-55     Citation Subset:  IM    
Affiliation:
Department of Cardiology, School of Medicine, Catholic University of the Sacred Heart, Rome, Italy. alfonso.sestito@rm.unicatt.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Antihypertensive Agents / pharmacology,  therapeutic use*
Cardiovascular Diseases / etiology*,  prevention & control*
Drug Therapy, Combination
Humans
Hypertension / complications,  drug therapy*
Patient Compliance
Renin-Angiotensin System / drug effects,  physiology
Tetrazoles / pharmacology,  therapeutic use*
Valine / analogs & derivatives*,  pharmacology,  therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Antihypertensive Agents; 0/Tetrazoles; 137862-53-4/valsartan; 7004-03-7/Valine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of oxidative stress in diabetic cardiomyopathy: an experimental study.
Next Document:  Hypertension management in diabetic patients.